Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 3/20 | 0.42 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.39 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.39 |
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.38 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 known ✓ | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 1/20 | 0.37 |
| ▸ | ACE known ✓ | P12821 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1912605 | 0.98 | EGLN1 (0.63) | EGLN1ALDH1A1SMN1; SMN2CYP2D6GAA | |
| SCHEMBL11314635 | 0.83 | EGLN1 (0.49) | EGLN1ALDH1A1SMN1; SMN2CYP2D6GAA | |
| Hydrochloric Acid SCHEMBL27762950 | 0.82 | GAA (0.57) | EGLN1ALDH1A1SMN1; SMN2GAAMGAM | |
| SCHEMBL11312087 | 0.80 | EGLN1 (0.46) | EGLN1ALDH1A1SMN1; SMN2CYP2D6GAA | |
| SCHEMBL13153845 | 0.80 | ACHE (0.50) | EGLN1ACHE | |
| SCHEMBL1923231 | 0.80 | EGLN1 (0.44) | EGLN1ALDH1A1SMN1; SMN2CYP2D6GAA | |
| Hydrochloric Acid SCHEMBL2185194 | 0.79 | ACHE (0.56) | ALDH1A1ACHE | |
| SCHEMBL2482646 | 0.79 | GAA (0.59) | EGLN1ALDH1A1SMN1; SMN2GAAMGAM | |
| SCHEMBL2651973 | 0.79 | ALDH1A1 (0.46) | EGLN1ALDH1A1SMN1; SMN2GAAMGAM | |
| Hydrochloric Acid SCHEMBL27336202 | 0.78 | HDAC3 (0.45) | EGLN1GLAKMT2AACHEHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110384676-A | The good dextrorotation oxiracetam capsule and preparation method thereof of stability | 重庆润泽医药有限公司 | 2019-10-29 | — | — | CN | disclosed |
| CN-110381949-A | Heterocyclic compound and application thereof | 石全 | 2019-10-25 | — | — | CN | disclosed |
| CN-106458934-B | Quinoxaline compounds and application thereof | 米伦纽姆医药公司 | 2019-08-16 | — | — | CN | disclosed |
| CN-109824670-A | The polymorph and its preparation method and application of pteridinone class compound or its salt | 四川科伦博泰生物医药股份有限公司 | 2019-05-31 | — | — | CN | disclosed |
| CN-106349145-B | A method of preparing nootropics (S)-Oxiracetam | 徐敏 | 2018-11-20 | — | — | CN | disclosed |
| CN-106349145-A | Method for preparing intelligence-improving medicine (S)-oxiracetam | 青岛云天生物技术有限公司 | 2017-01-25 | — | — | CN | disclosed |
| CN-104693176-A | Pyrrole derivative, preparation method and purpose thereof | UNIV EAST CHINA SCIENCE & TECH | 2015-06-10 | — | — | CN | disclosed |
| CN-101896482-B | Thiophene derivatives as S1P1/EDG1 agonists | ACTELION PHARMACEUTICALS LTD | 2013-01-09 | — | — | CN | disclosed |
| CN-101896482-A | Thiophene derivatives as S1P1/EDG1 agonists | ACTELION PHARMACEUTICALS LTD | 2010-11-24 | — | — | CN | disclosed |
| CN-101166756-A | Pyrimidine derivatives and their use as p2y12 receptor antagonists | ACTELION PHARMACEUTICALS LTD (CH) | 2008-04-23 | — | — | CN | disclosed |